CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...

Mr. Pasternak brings decades of global pharmaceutical leadership experienceTransition further highlights transformation of the Board to lead ...

Context Therapeutics (CNTX) announced the appointment of Andy Pasternak as Chairman of its Board of Directors, succeeding Richard Berman, who ...

Context Therapeutics has dosed the first subject in the Phase I trial of CTIM-76, targeting claudin 6 (CLDN6)-positive ...

Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...

CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...

Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...

PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a company specializing in T cell engaging therapies for solid tumors, announced today the appointment of Andy Pasternak as its new Chairman ...

PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...

PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...